Misinformation about vaccines has swirled online since US President Donald Trump appointed Robert F. Kennedy Jr. – who has ...

Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...

Vaccine hesitancy and higher rates of school vaccine exemptions increases the risk of outbreaks of preventable diseases, creating a significant health risk for vulnerable populations.

ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leading biotech” to discover new antibody-drug ...

Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...

The mRNA technology behind coronavirus vaccines is now being used to create bespoke vaccines for cancer patients.

Truist analyst Asthika Goonewardene lowered the firm’s price target on BioNTech (BNTX) to $151 from $172 and keeps a Buy rating on the shares.

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...